Table 1 Baseline characteristics.

From: GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours

Group

GX-I7 60 µg/kg (n = 3)

GX-I7 120 µg/kg (n = 3)

GX-I7240 µg/kg (n = 3)

GX-I7 480 µg/kg (n = 3)

GX-I7 720 µg/kg (n = 6)

GX-I7 960 µg/kg (n = 3)

GX-I7 1200 µg/kg (n = 12)

GX-I7 1700 µg/kg (n = 2)

Total (n = 35)

Age (years)

Median (Min, Max)

58 (52, 64)

58 (55, 58)

59 (52, 75)

44 (44, 48)

57 (45, 71)

58 (45, 65)

62 (43, 75)

54 (48, 60)

58 (40, 75)

Gender, N (%)

 Male

2 (67)

0

3 (100)

2 (67)

4 (67)

1 (33)

6 (50)

1 (50)

19 (54)

Race, N (%)

 Asian

3 (100)

3 (100)

3 (100)

3 (100)

6 (100)

3 (100)

12 (100)

2 (100)

35 (100)

ECOG performance status, N >(%)

 0

1 (33)

1 (33)

1 (33)

0

5 (83)

2 (67)

5 (42)

2 (100)

17 (49)

 1

2 (67)

2 (67)

2 (67)

3 (100)

1 (17)

1 (33)

7 (58)

0

18 (51)

Site of Primary Tumour, N (%)

 Breast

1 (33)

0

0

1 (33)

0

0

2 (17)

0

4 (11)

 Colon/Rectal

1 (33)

2 (67)

2 (67)

2 (67)

4 (67)

3 (100)

7 (58)

2 (100)

23 (66)

 Ovary

0

1 (33)

0

0

0

0

2 (17)

0

3 (9)

 Other

1 (33)

0

1 (33)

0

2 (33)

0

1 (8)

0

5 (14)

Location of Metastatic, N

 Abdominal Wall

0

1

0

0

1

1

1

0

4

 Adrenal Gland

1

0

1

0

0

0

1

0

3

 Bone

1

0

0

1

1

0

1

0

4

 Brain

0

0

0

1

0

0

1

0

2

 Liver

2

2

2

2

1

3

10

2

24

 Lung

3

2

3

3

5

3

11

2

32

 Lymph Node

2

2

1

2

3

2

2

0

14

 Pleura

1

0

0

0

0

0

1

0

2

 Other

2

0

2

1

2

2

4

0

13

Previous illness of systemic therapy, N (%)

 0

0

0

0

0

0

0

1 (8)

0

1 (3)

 1

0

0

0

0

0

0

0

0

0

 2

0

0

1 (33)

1 (33)

1 (17)

0

1 (8)

0

4 (11)

 3

1 (33)

0

0

0

4 (67)

1(33)

5 (42)

2 (100)

13 (37)

 ≥4

2 (67)

3 (100)

2 (67)

2 (67)

1 (17)

2 (67)

5 (42)

0

17 (49)

  1. ECOG PS Eastern Cooperative Oncology Group performance status.
  2. †Patient received chemotherapy for adjuvant.